Milestone
Helio Genomics was founded, with the earliest cancer-detection methylation profile, including thousands of novel methylation biomarkers.
Our Story
Helio is focused on saving lives by detecting cancer early.
Since 2016
What We Do
An AI Healthcare Company on a Mission
Helio Genomics is an AI-driven healthcare company pioneering the early detection of cancer through a simple blood test. We combine DNA methylation science with machine learning and nearly a decade of research to find cancer at its earliest, most treatable stage, beginning with the liver and building toward many more.
Our Founding Philosophy
We're Explorers of the Unknown
Our founding principles are rooted in a desire to challenge the unknown. We harness the power of big data to make sense of how nature exists and evolves, so we can understand how it affects each of us individually. We believe our technology can change how the world sees disease, beginning by making cancer something people survive, and easing the high cost and emotional burden it places on society today.
Our Approach
The Science Behind Early Detection
We built a multi-analyte platform, our proprietary ECLIPSE™ technology, that reads the molecular signals of cancer from a simple blood draw. By reading cfDNA methylation patterns alongside protein markers and clinical data, and interpreting them with machine learning, we can detect cancer earlier and more accurately than many traditional methods. It is a simpler, smarter path to the answers that matter most.
cfDNA methylation
Protein markers
Clinical data
Machine learning
ECLIPSE™
By the Numbers
Built on Real Science
2016
The year Helio Genomics was founded
6
Peer-reviewed publications, including Nature Materials, PNAS, Nature Communications, and the Journal of Hepatology
5
Clinical studies, including ENCORE and the pivotal CLiMB
Thousands
Methylation biomarkers
Our Journey
Our Journey So Far
Milestone
First publications on using methylation for early cancer detection, in Nature Materials and PNAS.
Milestone
Published a new AI and machine-learning prediction method for early cancer detection (CHALM) in Nature Communications.
Milestone
Completed the ENCORE trial, a prospective, blinded, multicenter Phase 2 study showing HelioLiver’s performance in detecting early-stage HCC. Launched HelioLiver, our flagship blood-based test.
Milestone
ENCORE results published in Hepatology Communications, highlighting the ECLIPSE platform and HelioLiver algorithm.
Milestone
CLiMB pivotal trial data presented at the EASL Congress and AASLD.
New milestone
New leadership, with Bharat Tewarie appointed CEO, is guiding HelioLiver into wider clinical use.
New milestone
CLiMB trial published in the Journal of Hepatology. Strategic commercial partnership with Syneos Health announced.
What Drives Us
What Drives Us
Science First
Every claim we make is grounded in peer-reviewed research and validated in clinical trials.
Access for All
Early detection should be simple, affordable, and within reach. A blood draw, not a barrier.
Relentless Curiosity
We are explorers of the unknown, always challenging what is possible in cancer detection.
Where We're Going
HelioLiver Is Just the Beginning
Our platform is built to expand across more cancers, into minimal residual disease monitoring, and toward a future where catching cancer early is a routine part of everyone's care. HelioLiver proved what is possible. Now we are building the company that makes cancer a disease people survive.
Meet the Team
The People Behind the Mission
Behind this work is a team of scientists, physicians, and industry leaders united by a single goal: to make cancer a disease people survive.
Meet Our Team